Qure.ai netsย $65M forย foundational AIย
Qure.ai has raised $65 million in a Collection D funding spherical led by Lightspeed and 360 ONE Asset.ย
The corporate mentioned it should use its contemporary funds to speculate extra in foundational AI fashions, in addition to purchase complementary startups in medical expertise. It would even be used to speed up its enlargement in the US and different markets.ย
Early this 12 months, the Mumbai-based firm obtained two main clearances from the US Meals and Drug Administration: a breakthrough machine designation for its tuberculosis screening AI answer, qSpot-TB, and a 510(ok) clearance for the lung nodule on the qXR AI-powered chest X-ray software program.
Mediwhale luggage $12M to hunt US FDA approvalย
South Korean well being diagnostics agency Mediwhale has scored $12 million in a Collection A2 funding spherical led by the Korea Growth Financial institution.ย
The corporate claims to supply the world’s first retina-based answer โ known as Reti-CVD โย that makes use of AI to evaluate heart problems danger.ย
It plans to make use of its new funds to pursue a US FDA approval for Reti-CVD. The software program was reportedly rolled out throughout the Yonsei College Well being System early this 12 months.ย
“We’re decided to safe FDA De Novo approval by 2025, with plans to launch our product in the US shortly thereafter,” CEO Kevin Choi mentioned in a press release.ย
In addition to securing a regulatory clearance, Mediwhale additionally seeks to enhance its AI additional and develop new options to foretell persistent kidney illness danger.ย
Mediwhale final raised $2 million in a pre-Collection A funding spherical in 2021 and $9 million in a Collection A spherical in 2023.ย
Huawei launches medical imaging AIย
Huawei lately unveiled a brand new AI-powered answer for analysing medical pictures.ย
Referred to as “Medical Expertise Digitalization 2.0,” the expertise allows sensible segmentation, detection, and quantitative evaluation of medical pictures utilizing AI with as much as 98% accuracy. Huawei claims the answer can shorten illness prognosis time by 40%, though it has not specified which illness.ย
Moreover, the AI answer may also be utilized to ultrasound gadgets operating on the OpenHarmony working system.
The Chinese language tech large labored with a number of native medical expertise corporations, together with MED Imaging AI, Wanxiang, Beijing DeepWise, and KFBIO, to develop the answer, which has been applied in such main tasks because the Fourth Individuals’s Hospital in Shenyang, capital of Chinaโs northeast Liaoning Province.ย
Korean pharma turns to AI forย new drug discovery
Korean pharmaceutical firm GI Innovation is pursuing the applying of AI for brand new drug growth.ย
It lately signed a memorandum of understanding with native firm i-Divine to develop its core most cancers drug pipelines and utilise the latter’s AI answer to find new most cancers remedy targets.ย
i-Divine’s AI relies on a big language mannequin educatedย on over a billion patents, papers, and real-time organic knowledge sourced globally. It was beforehand utilised to analyse the success potential of 16,000 new drug substances, together with one in all GI Innovation’s anti-cancer drug pipelines.ย ย
MediBuddy adopts Philips’ predictive coronary heart AIย
MediBuddy in India is integrating Philips’ coronary heart well being monitoring platform into its cellular well being software.ย
The AI-based longitudinal triaging answer known as HeartPrint tracks and assesses key biomarkers from an individual’s finger when scanned via their smartphone’s digital camera. These embody cardiovascular age, diabetes danger, OSA danger, cardio-respiratory health index, coronary heart charge evaluation, cardiac index, blood strain variability, and stress dysfunction prediction.ย
The AI answer additionally analyses patterns indicating an individual’s danger of creating coronary heart illness, total well being deterioration, coronary heart resilience, and quick and long-term adjustments in cardiac perform.
